Newsletter Volume 39, Number 3, 2024
Introduction
We are approaching the turn of the year 2024. The rainy season seems to start later than usual this year. During the rainy season, which is often gloomy and rainy, going out tends to be a chore, but I look forward to going out to see hydrangeas in Kamakura, which is not far from my house. There are many places of interest, but I especially recommend Myogetsuin Temple in Kita-Kamakura, where the pathway covered with bright blue hydrangeas, called “Myogetsuin blue,” is breathtakingly beautiful. It seems that hydrangeas became famous in Kamakura when the priest of Myogetsuin Temple started planting them to heal the hearts of people devastated by World War II. Since hydrangeas turn blue in slightly acidic soil, the acidity of the soil is adjusted with fertilizers, etc. by early spring to maintain their color.
In recent years, however, Kamakura has been overflowing with an unprecedented number of people, perhaps due to over-tourism, and it is no longer possible to take a leisurely stroll in Kamakura as it used to be. Often, tourists form a several dozen meter long queue in front of the ticket gate at Kamakura Station of the Enoshima Electric Railway, and from there to the nearest station of Hase-dera Temple, another famous hydrangea viewing spot, it is faster to walk than to take the train because of the overcrowding. Foreign tourists have also flooded the railroad crossing of the Enoshima Electric Railway, which is associated with the popular manga “Slam Dunk,” and have become a major social problem, blocking the passage of vehicles as tourists spread out on the roadway to take pictures. Overtourism has spread worldwide since the end of the Corona crisis, and Hawaii, where the 39th Annual Meeting of the Japanese Society of Pharmacokinetics and Pharmacodynamics (JSPS) will be held in mid-September, is no exception. There are many attractive tourist spots such as Waikiki Beach, Diamond Head, Ala Moana Shopping Center, and the statue of King Kamehameha the Great, which will make you feel very open-minded. I hope you will enjoy your time in Hawaii while maintaining moderation as a Japanese citizen and a representative pharmacokinetic researcher of Japan. (Y.M.)
NEW POWER for pharmacokinetic research
Toward Optimization of Drug Administration during Hypothermia
Assistant Professor, Department of Pharmacology, Nagasaki University
Keiten Miyamoto
My name is Keiten Miyamoto and I am an Assistant Professor in the Department of Pharmaceutics, Nagasaki University, Faculty of Life Science and Medical Bioscience. I would like to take this opportunity to thank the editorial board members and all those involved for the opportunity to contribute to the newsletter of the Japanese Society of Pharmacokinetics and Pharmacodynamics, “NEW POWER for Pharmacokinetics Research. I entered the Faculty of Pharmaceutical Sciences of Nagasaki University in 2004 and started my pharmacokinetic research in the Laboratory of Pharmacokinetics led by Dr. Junzo Nakamura in my fourth year of undergraduate studies.
In this paper, I would like to review my research and introduce my efforts as a practitioner faculty member. … ( To be continued at NL website / Members Only )
Antibody Drug Conjugate (ADC) Pharmacokinetic Studies
Part 5: Analysis and ADME Evaluation of ADCs in Preclinical Stage and Modeling & Simulation
Pharmacokinetic Research Institute, Daiichi Sankyo Company, Limited
Hiromi Okamoto, Yoko Nagai
Hello! In this last issue of “Introduction to Pharmacokinetic Studies of Antibody Drug Conjugates (ADCs),” I would like to review basic information on the timing of obtaining various pharmacokinetic study data in preclinical studies of ADCs and modeling and simulation of ADCs. I would like to talk about modeling and simulation of ADCs.
As discussed in the first article, ADC is a modality that combines the advantages of “small molecule” and “antibody”. An ADC can expand the therapeutic window by maintaining the strong anti-tumor activity of a small molecule and reducing the strong side effects associated with nonspecific exposure to normal tissues by utilizing the high target tissue specificity of an antibody. In preclinical studies, it is necessary to understand the characteristics of ADCs based on the linker and binding site while simultaneously conducting ADME studies on the antibody, payload, and ADC. … ( To be continued at NL website / members only )